Currently out of the existing stock ratings of Pete Stavropoulos, 48 are a BUY (94.12%), 3 are a HOLD (5.88%).

Pete Stavropoulos

Work Performance Price Targets & Ratings Chart

Analyst Pete Stavropoulos, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 28% that have a potential upside of 62.25% achieved within 143 days.

Pete Stavropoulos’s has documented 82 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALEC, Alector at 22-Oct-2025.

Wall Street Analyst Pete Stavropoulos

Analyst best performing recommendations are on ORTX (ORCHARD THERAPEUTICS PLC).
The best stock recommendation documented was for ORTX (ORCHARD THERAPEUTICS PLC) at 6/27/2023. The price target of $15 was fulfilled within 100 days with a profit of $9.77 (186.81%) receiving and performance score of 18.68.

Average potential price target upside

of $22.45 (125.99%) on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
of $9.85 (191.34%) on ORTX (ORCHARD THERAPEUTICS PLC).
of $4.28 (248.61%) on RZLT (REZOLUTE).

ANNX Annexon PLRX Pliant Therapeutics ARCT Arcturus Therapeutics Holdings ORTX Orchard Therapeutics PLC RZLT Rezolute ABOS Acumen Pharmaceuticals ALEC Alector VERA Vera Therapeutics VSTM Verastem VYGR Voyager Therapeutics JSPR Jasper Therapeutics ELDN Eledon Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Derek Archila (WELLS FARGO)